Phase Ib study of BT1718 for the treatment of solid tumours
Latest Information Update: 07 Jul 2017
Price :
$35 *
At a glance
- Drugs BT 1718 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 06 Jul 2017 According to Pepscan Therapeutics media release, Cancer Research UK, will sponsor and fund the trial.
- 21 Dec 2016 New trial record